A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients with Solid Tumours
Latest Information Update: 19 Feb 2025
At a glance
- Drugs GT 307 (Primary)
- Indications Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors GRIT Biotechnology
Most Recent Events
- 13 Jun 2024 New trial record